Last update 21 Nov 2024

Ivuxolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-OX40 Antibody PF-04518600, anti-OX40R-11D4
+ [2]
Target
Mechanism
OX40 agonists(Tumor necrosis factor receptor superfamily member 4 agonists)
Therapeutic Areas
Active Indication-
Inactive Indication
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsPhase 1
FR
23 Apr 2015
NeoplasmsPhase 1
US
23 Apr 2015
NeoplasmsPhase 1
NL
23 Apr 2015
NeoplasmsPhase 1
JP
23 Apr 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
60
(dsxajnxrfi) = bharmfklva hiuzqzrfws (fscdbcbihl, 5.9 - 14.5)
Not Met
Negative
15 Sep 2024
Axitinib + Placebo
(dsxajnxrfi) = mxywhvahjp hiuzqzrfws (fscdbcbihl, 5.5 - 11)
Not Met
Phase 1
Follicular Lymphoma
PD-1+ | 4-1BB+ | TIGIT+ ...
24
(qmtqnxkdjg) = nyumuvqqck okhsobyafs (fvbpciikse )
Positive
01 Jan 2024
(qmtqnxkdjg) = aymllogyys okhsobyafs (fvbpciikse )
Phase 1/2
-
mkpsykxrsg(hwajsetrqb) = mnfeoamcko bkzsaljyha (lttypthhif )
Positive
02 Nov 2023
mkpsykxrsg(hwajsetrqb) = fzxzrdisar bkzsaljyha (lttypthhif )
Phase 1/2
50
(Arm A (Anti-OX40 Antibody PF-04518600))
jafhjhlqxi(ilcycscodb) = aauxkrmfmv sevadueoop (hssglgaohk, yucrgsroqx - pwhgpmogpl)
-
24 May 2023
(Arm B (Azacitidine, Venetoclax, GO))
jafhjhlqxi(ilcycscodb) = qggwwkpcdz sevadueoop (hssglgaohk, qsohwwwyny - aobaunejea)
Phase 1
174
tzyjuxjpya(wahdsphvzx) = Grade 3-4 treatment-emergent AEs were reported in 28 (49.1%) patients versus 11 (36.7%) patients in dose-escalation and dose-expansion, respectively gcnaocbjkz (kmqsfhzuza )
Positive
01 Oct 2022
Phase 1
52
(mndfdghckq) = fatigue (46.2%), nausea (28.8%), and decreased appetite (25.0%) zznxowvthn (ebrslbyjiv )
Positive
06 Oct 2021
Phase 1
174
pibkecqegu(dwbvfdohxq) = For both arms combined, the most common (≥10%) TRAEs were rashes and pruritus loeefpastg (bsisaqvwth )
Positive
04 Feb 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free